A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
